Ceftazidime and avibactam
Products billed under this code include Avycaz.
Payment limit per .625 GM, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Avycaz.
Payment limit per .625 GM, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Avycaz | Allergan, Inc. | 00456-2700-10 | 40 | $4,378.16 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $109.454 | −$0.314 | .625 GM | Ceftazidime and avibactam | v1, posted September 17, 2026 |
| 3Q26 | $109.768 | +$5.019 | .625 GM | Ceftazidime and avibactam | v1, posted September 15, 2026 |
| 2Q26 | $104.749 | +$0.04 | .625 GM | Ceftazidime and avibactam | v1, posted September 15, 2026 |
| 1Q26 | $104.709 | −$0.021 | .625 GM | Ceftazidime and avibactam | v1, posted September 15, 2026 |
| 4Q25 | $104.73 | −$0.22 | .625 GM | Ceftazidime and avibactam | v1, posted September 8, 2026 |
| 3Q25 | $104.95 | +$4.454 | .625 GM | Ceftazidime and avibactam | v1, posted March 10, 2026 |
| 2Q25 | $100.496 | −$0.231 | .625 GM | Ceftazidime and avibactam | v1, posted March 10, 2026 |
| 1Q25 | $100.727 | +$0.145 | .625 GM | Ceftazidime and avibactam | v1, posted December 19, 2025 |
| 4Q24 | $100.582 | +$0.382 | .625 GM | Ceftazidime and avibactam | v1, posted June 11, 2025 |
| 3Q24 | $100.20 | +$4.764 | .625 GM | Ceftazidime and avibactam | v1, posted June 11, 2025 |
| 2Q24 | $95.436 | −$0.013 | .625 GM | Ceftazidime and avibactam | v1, posted March 11, 2025 |
| 1Q24 | $95.449 | +$0.012 | .625 GM | Ceftazidime and avibactam | v1, posted December 19, 2024 |
| 4Q23 | $95.437 | +$2.958 | .625 GM | Ceftazidime and avibactam | v1, posted October 10, 2024 |
| 3Q23 | $92.479 | +$1.641 | .625 GM | Ceftazidime and avibactam | v1, posted June 5, 2024 |
| 2Q23 | $90.838 | −$0.531 | .625 GM | Ceftazidime and avibactam | v1, posted February 23, 2024 |
| 1Q23 | $91.369 | −$0.273 | .625 GM | Ceftazidime and avibactam | v1, posted December 6, 2023 |
| 4Q22 | $91.642 | −$0.144 | .625 GM | Ceftazidime and avibactam | v1, posted June 22, 2023 |
| 3Q22 | $91.786 | −$0.008 | .625 GM | Ceftazidime and avibactam | v1, posted June 9, 2023 |
| 2Q22 | $91.794 | −$0.58 | .625 GM | Ceftazidime and avibactam | v1, posted December 14, 2022 |
| 1Q22 | $92.374 | −$0.02 | .625 GM | Ceftazidime and avibactam | v1, posted June 8, 2022 |
| 4Q21 | $92.394 | −$0.066 | .625 GM | Ceftazidime and avibactam | v1, posted June 2, 2022 |
| 3Q21 | $92.46 | +$0.01 | .625 GM | Ceftazidime and avibactam | v1, posted June 2, 2022 |
| 2Q21 | $92.45 | +$0.167 | .625 GM | Ceftazidime and avibactam | v1, posted March 1, 2022 |
| 1Q21 | $92.283 | – | .625 GM | Ceftazidime and avibactam | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.